Copegus

Minutes late ; . Ensure that when you plan your course, you have an option to cut parts off it and return to the HH if time is tight. Carry the mandatory equipment. Don't be tempted to ditch the first aid kit, safety blanket, waterproof jacket, or whistle to try and save weight. This is the falsest of economies! When needed, they are worth their weight in gold. You can use only a map and compass for navigation. This means no GPS, pedometers or altimeters.

WARNINGS COPEGUS must not be used alone because ribavirin monotherapy is not effective for the treatment of chronic hepatitis C virus infection. The safety and efficacy of COPEGUS have only been established when used together with PEGASYS pegylated interferon alfa-2a, recombinant ; . COPEGUS and PEGASYS should be discontinued in patients who develop evidence of hepatic decompensation during treatment. There are significant adverse events caused by COPEGUS PEGASYS therapy, including severe depression and suicidal ideation, hemolytic anemia, suppression of bone marrow function, autoimmune and infectious disorders, pulmonary dysfunction, pancreatitis, and diabetes. The PEGASYS package insert and MEDICATION GUIDE should be reviewed in their entirety prior to initiation of combination treatment for additional safety information. The benefits described in Sections 7.2 d ; 1 ; and d ; 4 ; shall be paid in cash to the Executive in a single lump sum as soon as practicable following the Effective Date of Termination, but in no event beyond thirty 30 ; days from such date. All other payments due to the Executive upon termination of employment, including those in Sections 7.2 d ; 2 ; and d ; 3 ; , shall be paid in accordance with the terms of such applicable plans or program. With the exception of the covenants contained in Articles 8, 9, 11, and 14 and Sections 7.2 e ; , 13.3, 13.5, and 13.7 herein which shall survive such termination ; , the Company and the Executive thereafter shall have no further obligations under this Agreement. 8 and leukeran.
Pharmaceuticals is committed to improving health and quality of life by focusing on the discovery, development, manufacture and marketing of innovative prescription medications.
Effective with date of service June 1, 2005, the N.C. Medicaid program covers peginterferon alfa-2a Pegasys ; for use in the Physician's Drug Program when billed with HCPCS code J3490. Pegasys is a covalent conjugate of recombinant alfa-2a interferon with a polyethylene glycol PEG ; chain. The FDA approved indications for Pegasys are: Alone or in combination with Ccopegus ribavirin ; for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis Child-Pugh class A ; and patients with HIV disease that is clinically stable e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy ; . For the treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation. The recommended dosing schedules are provided below. For Patients with Chronic Hepatitis C: Pegasys monotherapy: 180 mcg SQ once weekly for 48 weeks Pegasys and Copegis combination therapy: Viral Genotype Genotypes 1, 4 Genotypes 2, 3 Pegasys Dose SQ once weekly ; 180 mcg 180 mcg Cpegus Dose PO daily in 2 divided doses ; 75 kg 1000 mg 75 kg 1200 mg 800 mg Duration 48 weeks 48 weeks 24 weeks and viramune.

About Pharmasset Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus HBV ; , hepatitis C virus HCV ; and human immunodeficiency virus HIV ; . Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is enrolling a 28-day Phase 1 clinical trial in combination with Pegasys and Fopegus through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial. About R7128 R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up to 3000 mg. R7128 Phase 1 Study Overview The Phase 1 clinical trial is a multiple center, observer-blinded, randomized and placebo-controlled study to investigate the pharmacokinetics, pharmacodynamics, safety, tolerability and food effect of R7128 in healthy volunteers and in patients chronically infected with HCV genotype 1. This adaptive Phase 1 study is comprised of three parts: Part 1 is a single ascending dose study of R7128 conducted in 46 healthy volunteers. The primary objective of Part 1 is to assess the safety, tolerability and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of Part 1 is to explore the effect of food on the pharmacokinetics of R7128. Results from the single ascending dose portion of the study indicated that all doses of R7128 studied 500 mg to 9000 mg ; were generally safe and well-tolerated. All patients completed the study, and none experienced gastrointestinal adverse events or serious adverse events during the study. No hematological or laboratory abnormalities of clinical significance were noted. Part 2 is a multiple ascending dose study of R7128 conducted in 40 patients chronically-infected with HCV genotype 1 who previously failed interferon therapy. The primary objective of Part 2 is to assess the safety, tolerability and pharmacokinetics of R7128 after once-daily QD ; or twice-daily BID ; dosing for 14 days. The secondary objective is to assess antiviral activity by measuring the change in HCV RNA. Preliminary data from the multiple ascending dose portion of the study indicated that R7128 demonstrated potent, dose-dependent antiviral activity in four patient cohorts receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. Patients receiving 1500 mg BID demonstrated a mean 2.7 log10 IU ml and mysoline.

The empirical formula of ribavirin is C8H12N4O5 and the molecular weight is 244.2. Ribavirin is a white to off-white powder. It is freely soluble in water and slightly soluble in anhydrous alcohol. COPEGUS ribavirin ; is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium.

Patients treated for 24 weeks with PEGASYS and 800 mg COPEGUS were observed to have lower incidence of serious adverse events 3% vs 10% ; , hemoglobin 10g dL 3% vs 15% ; , dose modification of PEGASYS 30% vs 36% ; and COPEGUS 19% vs 38% ; and of withdrawal from treatment 5% vs 15% ; compared to patients treated for 48 weeks with PEGASYS and 1000 mg or 1200 mg COPEGUS. On the other hand the overall incidence of adverse events appeared to be similar in the two treatment groups. The most common serious adverse event 3% ; was bacterial infection eg, sepsis, osteomyelitis, endocarditis, pyelonephritis, pneumonia ; . Other SAEs occurred at a frequency of 1% and included: suicide, suicidal ideation, psychosis, aggression, anxiety, drug abuse and drug overdose, angina, hepatic dysfunction, fatty liver, cholangitis, arrhythmia, diabetes mellitus, autoimmune phenomena eg, hyperthyroidism, hypothyroidism, sarcoidosis, systemic lupus erythematosis, rheumatoid arthritis ; peripheral neuropathy, aplastic anemia, peptic ulcer, gastrointestinal bleeding, pancreatitis, colitis, corneal ulcer, pulmonary embolism, coma, myositis, and cerebral hemorrhage. Laboratory Test Values Anemia due to hemolysis is the most significant toxicity of ribavirin therapy. Anemia hemoglobin 10 g dL ; was observed in 13% of COPEGUS and PEGASYS combination-treated patients in clinical trials. The maximum drop in hemoglobin occurred during the first 8 weeks of initiation of ribavirin therapy see DOSAGE AND ADMINISTRATION: Dose Modifications ; . OVERDOSAGE No cases of overdose with COPEGUS have been reported in clinical trials. DOSAGE AND ADMINISTRATION The recommended dose of COPEGUS tablets is provided in Table 4. The recommended duration of treatment for patients previously untreated with ribavirin and interferon is 24 to weeks. The daily dose of COPEGUS is 800 mg to 1200 mg administered orally in two divided doses. The dose should be individualized to the patient depending on baseline disease characteristics eg, genotype ; , response to therapy, and tolerability of the regimen see Table 4 and oxytrol. In primates, studies of LID have focused mainly on the activity of the internal segment of the globus pallidus GPi ; , the larger of the two output nuclei of the BG, and have neglected the substantia nigra pars reticulata SNr ; . Although these two nuclei are often clumped together as the output stage of the BG, they differ in a number of critical ways. One significant difference is the targets of innervation of these nuclei. Although both nuclei project to the thalamus, only the SNr projects to the superior collliculus SC ; , a crucial brain stem structure for orienting and spatial attention processes Guitton et al., 2003; Wurtz et al., 2001 ; . The SNr and GPi also differ in the type of movements associated with their activity: the SNr has been shown to be primarily related to ocular and orofacial movements DeLong et al., 1983; Hikosaka and Wurtz, 1983; Schultz, 1986.
PEGASYS peginterferon alfa-2a ; 298 299 300 PEGASYS is contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurologic and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS combination therapy is additionally contraindicated in: Patients with known hypersensitivity to COPEGUS or to any component of the tablet Women who are pregnant Men whose female partners are pregnant Patients with hemoglobinopathies e.g., thalassemia major, sickle-cell anemia and topamax. And rat ; must be understood critically with respect to prevailing technical limitations. First, with contemporary methodologies, GH secretion rate estimates are stable on successive control days in healthy men 81 ; . Second, the majority of prior RIA and IRMA estimates of serum GH concentrations had an absolute sensitivity of 0.1 0.5 g liter. Thus, in middle-aged and older, obese, hypothyroid, or fed healthy humans, daytime serum GH concentrations can fall below such assay thresholds in 20 97% of blood samples 118, 119 ; . Consequently, the recent emergence of immunofluorometric and chemiluminescence GH assays with 10- to 30-fold increased sensitivity have provided new insights into the regulation of GH release during daytime hours and in selected pathophysiologies 118, 119 ; . For example, an ultrasensitive chemiluminescence assay disclosed the existence of a 140fold range in mean serum GH concentrations in healthy men. In addition, the assay suggested that a low rate of basal GH secretion exists between distinct GH-secretory bursts. Similar results were obtained in three independent ELISA-based studies 122124 ; . Notably, low basal rates of GH release were correlated to the serum concentration of estrogen as well as influenced by age and body composition 120 ; . In the high-sensitivity chemiluminescence assay, all blood samples in more than 100 individuals spanning a range of ages and body compositions and pathophysiologies have contained detectable GH concentrations sensitivity limits 0.002 g liter at 2 sds and 0.005 g liter at 4 sds above blank ; 119 ; . This assay further revealed that serum GH concentrations are suppressed by glucose to less than 0.7 g liter in healthy women and less than 0.07 g liter in healthy men, evincing a novel sex distinction in GH axis function 120 ; . Other studies with a high-sensitivity 0.013 g liter threshold ; immunofluorometric assay in middle-aged and perimenopausal women and age-matched men show that the quantitative basis for the gender difference in pulsatile GH release arises from higher GH-secretory burst mass pulse amplitude and duration ; in women compared with men, with no evident differences in the GH half-life or GH-secretory burst frequency 118 ; . Postpartum relative hyposomatotropism in the mother is also recognized in the human 1026 ; . Although the neuroendocrine mechanisms are not established, suppression of pituitary GH secretion by the placental GH variant V ; synthesized during pregnancy is possible 10271029 ; . Interestingly, neither GHRH nor GHRP-1 is an effective GH secretagogue in this context, until PRL levels decline peripartally 1028 ; . If GH autonegative feedback is relevant in postpartum maternal GH deficiency, the reasons for such sustained inhibition of the GH axis in lactating women remains enigmatic. NDA 21-511 S-014 Page 12 Laboratory Tests Before beginning COPEGUS therapy, standard hematological and biochemical laboratory tests must be conducted for all patients. Pregnancy screening for women of childbearing potential must be done. After initiation of therapy, hematological tests should be performed at 2 weeks and 4 weeks and biochemical tests should be performed at 4 weeks. Additional testing should be performed periodically during therapy. Monthly pregnancy testing should be done during combination therapy and for 6 months after discontinuing therapy. The entrance criteria used for the clinical studies of COPEGUS and PEGASYS combination therapy may be considered as a guideline to acceptable baseline values for initiation of treatment: Platelet count 90, 000 cells mm3 as low as 75, 000 cells mm3 in patients with cirrhosis or 70, 000 cells mm3 in patients with CHC and HIV ; Absolute neutrophil count ANC ; 1500 cells mm3 TSH and T4 within normal limits or adequately controlled thyroid function ECG see WARNINGS ; CD4 + cell count 200 cells L or CD4 + cell count 100 cells L but 200 cells L and HIV-1 RNA 5000 copies ml in patients coinfected with HIV Hemoglobin 12 g dL for women and 13 g dL for men in CHC monoinfected patients Hemoglobin 11 g dL for women and 12 g dL for men in patients with CHC and HIV and atrovent and Buy copegus online. There are a number of natural and healthy ways to combat sleep problems. Unfortunately, in the wake of this sleep deprivation phenomenon one not-sonatural method has been promoted, pushed and employed the most pharmaceuticals. There is a very big problem with this approach: Prescription medications are ineffective in the long-term and carry a long list of potential side effects. Since the early 1990's, with the introduction of prescription pill Ambien, drug companies have realized that targeting people with sleeping disorders can be an extremely lucrative enterprise. Big pharma smelled big money, and ever since has been pumping hundreds of millions of dollars into advertising to get a piece of the sleep prescription pie. In 2005 drug companies spent nearly 350 million dollars on ads for sleep drugs alone. That is a lot of money to convince people that your pill holds the key to a restful night, but is only a fraction of how much the prescription sleep remedy market is worth - nearly 2 billion dollars. And this number is expected to increase to 5 billion dollars by 2010. If you are to believe the claims and hype of these multi-billion dollar pharmaceutical companies, they have a pill that can solve your sleeping problems. Their marketing departments would have you believe that their products provide a safe and simple way to achieve the rest you deserve. Apparently all of their efforts are working. Last year alone 43 million prescriptions were written an all time high. But how effective are they really, and what ugly side effects are associated with these so-called `wonder drugs'? Clearly there are a huge number of people proloftin 11. Mr Deady--This may not help but I will say it for the record. You asked about the independent review. I understand the point you are making but, and I not the only one saying it, after tomorrow it is very clear there is no change to the legislation in relation to PBAC recommendations. So there is nothing that affects the legislation in that area. To me at least it seems that the concern about the independent review is that somehow it was going to be able to overturn these decisions, and it cannot. CHAIR--I have heard those explanations, I have read the text and I understand all of that. I will go on to next question. An agreement such as this marks a point in time at which the parties agree on particular issues, but interests that exist in the community that want to see a different outcome continue to push their concerns. An agreement like this should be seen as the resolution of those issues at this point in time. Pressure continues over time; there may be a different resolution in the future according to the will of governments et cetera. We know what the US drug producers want and they have said so and it is on the public record. There is no argument about what their objectives are. We do not assume, do we, that this agreement marks for them an end to their pursuit of their goals and forever and a day they are going to put their cue in the rack and walk away and say, `No more pursuit of those goals as far as Australia is concerned.' We do not make that assumption, do we?' Mr Deady--No, we cannot make that assumption. With future governments and future US governments that are reviews and committees. CHAIR--So will the industry. Senator Brandis said it the other day: they are in business to make a profit and they want to maximise their opportunity for a profit. If there is an opportunity at some future time to press their case again--given they are on the public record, they are ardent advocates of their case and they pursue it with a degree of relentlessness--they will. We can expect these issues to be eternal almost. Mr Deady--I agree with that but I add the point that whether there is an FTA or not that is the situation, that is the real world. CHAIR--Of course. But an FTA opens up the question of being able to look at these things for them. The absence of an FTA means they have to look at them in the context of the WTO. Mr Deady--I do not agree with that. They could certainly raise these issues bilaterally. Industry put pressure on government all the time. CHAIR--Of course. I accept that correction. Mr Deady--What the framework of an FTA or trade agreement does in my view is to, at least to a certain extent, circumscribe those avenues for pressing these things. The Americans sat down in the early days of February and said to the government of Australia, `Yes, we wanted more in this area but this is a balanced outcome that we can accept and live with.' That is again the reality of what we did at the end of February. We have agreed to establish an independent review and the Americans have agreed to that. So if the pharmaceutical industry continues to press its interests, which it will, the government of the day can say: `There is an independent review here. Off you go and make your case to it.' and combivent.

PRINCETON, N.J., Oct 24, 2007 PRNewswire-FirstCall via COMTEX News Network -- Pharmasset, Inc. Nasdaq: VRUS ; has received fast track designation from the U.S. Food and Drug Administration FDA ; for R7128 for the treatment of chronic hepatitis C virus HCV ; infection. R7128 is a prodrug of PSI-6130, an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche. Pharmasset is currently enrolling a 28-day Phase 1 clinical trial to evaluate R7128 in combination with Pegasys R ; pegylated interferon ; plus Cpoegus R ; ribavirin ; in treatment-naive patients chronically infected with hepatitis C virus HCV ; genotype 1. Please see clinicaltrials.gov or e-mail clinicaltrials pharmasset for more information. Under the FDA Modernization Act of 1997, fast track designation may facilitate the development and expedite the review of a drug candidate that is intended for the treatment of a serious life-threatening condition and demonstrates the potential to address an unmet medical need for such a condition. R7128 was granted the fast track designation primarily due to the need for HCV treatments with novel mechanisms of action, oral administration, different resistance profiles and improved safety and efficacy over the existing standard of care for both treatment-naive and treatment-experienced patients. "The FDA's fast track designation for R7128 acknowledges the urgent need for new HCV drugs, " stated Dr. Michelle Berrey, Pharmasset's Vice President, Clinical Development & Chief Medical Officer. "Currently, there are no HCV polymerase inhibitors approved for the treatment of chronic HCV infection. We continue to work closely with our HCV partner, Roche, and the FDA on the development and regulatory review of R7128, which has demonstrated compelling antiviral activity and has been generally well-tolerated in clinical trials to date." About Pharmasset Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus HBV ; , hepatitis C virus HCV ; and human immunodeficiency virus HIV ; . Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is enrolling a 28-day Phase 1 clinical trial in combination with Pegasys R ; and Copegus R ; through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial. About R7128 R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase. A prodrug is a chemically modified form of a molecule designed to enhance the absorption, distribution and metabolic properties of that molecule. Results from an oral single ascending dose study of PSI6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up to 3000 mg. R7128 Phase 1 Study Overview The Phase 1 clinical trial is a multiple center, observer-blinded, randomized and placebo-controlled study to investigate the pharmacokinetics, pharmacodynamics, safety, tolerability and food effect of R7128 in healthy volunteers and in patients chronically infected with HCV genotype 1. This adaptive Phase 1 study is comprised of three parts: Part 1 is a single ascending dose study of R7128 conducted in 46 healthy volunteers. The primary objective of Part 1 is to assess the safety, tolerability and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of Part 1 is to explore the effect of food on the pharmacokinetics of R7128. Results from the single ascending dose portion of the study indicated that all doses of R7128 studied 500 mg to 9000 mg ; were generally safe and well-tolerated. All patients completed the study, and none experienced gastrointestinal adverse events or serious adverse events during the study. No hematological or laboratory abnormalities of clinical significance were noted. Part 2 is a multiple ascending dose study of R7128 conducted in 40 patients chronically-infected with HCV genotype 1 who and buy epivir-hbv.

Keyomarsi, K. et al. 1991 ; Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51 13 ; , 3602-3609.
Poland increased , 003, 000 and revenues in Spain increased , 083, 000 primarily due to price increases and new product launches. Revenues in 2003 were negatively aected by the impact of German health care reform, reference-pricing litigation in Spain and price controls in Italy. In our Asia, Africa and Australia, or AAA, pharmaceuticals segment, revenues for the year ended December 31, 2003 were , 358, 000 compared to , 346, 000 for the same period of 2002, an increase of , 000. Revenues in AAA were aected by an increase in the value of currencies in the region of , 202, 000, oset by lower sales volume in several products including Fefol, Coracten and Reptilase. Reptilase sales were negatively impacted by licensing and renewal issues, which were resolved in the fourth quarter of 2003. Royalties: Royalty revenues in 2002 and 2001 represent amounts earned under the license and supply agreement with Schering-Plough, and for scal 2003, under a license agreement with Roche in addition to the license and supply agreement with Schering-Plough. Under the license and supply agreement, Schering-Plough licensed all oral forms of ribavirin for the treatment of chronic hepatitis C. In January 2003, we reached an agreement with Roche on a settlement of pending patent disputes over Roche's combination antiviral product containing Roche's version of ribavirin, known as Copegus. Under the agreement, Roche may continue to register and commercialize Copegus globally. The nancial terms of this settlement agreement include a license by us of ribavirin to Roche. The license authorizes Roche to make or have made and to sell Copegus under our patents in combination with interferon alfa or pegylated interferon alfa. Roche pays royalty fees to us on all sales of Copegus for use in combination with interferon alfa or pegylated interferon alfa. Royalties for the year ended December 31, 2003 from Schering-Plough and Roche were 7, 482, 000 compared to 0, 265, 000 for the same period of 2002, a decrease of 2, 783, 000 38% ; . The decrease in royalties include the eects of increasing competition between Schering-Plough and Roche, and Schering-Plough's provision for estimated rebates on its U.S. sales of ribavirin and changes in trade inventory levels as reported to us by Schering-Plough. We expected to also experience the impact of generic competition in the United States during the last half of 2003, but the U.S. Food and Drug Administration FDA ; did not grant approval for generic entrants by the year end. We continue to believe that approval of a generic form of oral ribavirin is imminent in the U.S. and that the impact of this approval will be a continued erosion of the royalty amount from sales in the United States. Royalties from sales of oral ribavirin outside the United States represent over half of total royalties for the year ended December 31, 2003. Gross Prot: Gross prot on product sales decreased to 64% for the year ended December 31, 2003 compared to 66% in 2002. The decrease in gross prot is primarily due to costs related to our manufacturing rationalization project incurred in 2003. These costs reect the impact of accelerated depreciation charges of , 609, 000 and severance charges of , 400, 000 associated with the rationalization eort. Selling Expenses: Selling expenses were 6, 707, 000 for the year ended December 31, 2003 compared to 4, 103, 000 for the same period in 2002, an increase of , 604, 000 2% ; . The increase reects our increased promotional eorts, mainly in Europe of , 004, 000 primarily related to the launch of Dermatix and the impact of changes in currencies, partially oset by a decrease in selling expenses in our North America pharmaceuticals segment of , 650, 000. General and Administrative Expenses: General and administrative expenses were 1, 532, 000 for the year ended December 31, 2003 compared to 6, 530, 000 for the same period in 2002, a decrease of 4, 998, 000 70% ; . Included in general and administrative expenses for the year ended December 31, 2002, are non-recurring and other unusual charges of 9, 965, 000, which primarily include: stock compensation costs related to the change of control under our Option Plan , 400, 000 severance costs , 216, 000 incentive compensation costs related to the accelerated vesting of restricted stock upon the change of control under our Long-Term Incentive Plan , 022, 000 executive and director bonuses paid in connection with Ribapharm's public oering , 839, 000 professional fees related to Ribapharm , 000, 000 the write-o of ICN International AG capitalized oering costs , 295, 000 the write-down of certain assets 23. Clots were determined to result from specimen integrity due to age of specimens. Invalid or not determined results were caused by insufficient sample 7 ABSC ; and varying reactivity among the 3 methodologies 24 ABSC, 32 DAT, 4 XM ; . Rouleaux was a known factor in one specimen ABSC ; . Eight XM discrepancies were due to deliberate test of the system with ABO mismatch. The 2 WD presented with positive DATs. Conclusion: Clotting and insufficient specimen issues were resolved by use of freshly collected specimens. Varying degree of reactivity should be expected with different methodologies, therefore, tests demonstrating invalid or not determined results should be repeated on the Galileo or investigated further with an alternate methodology. Evaluation of the Galileo automated system performed according to manufacturer's expectations and was determined acceptable for testing in this laboratory. SP338 Achieving Reduced Cycle Times for Pretransfusion Testing with Test Order Entry Modifications on Automation C Colavecchia ahmed.coovadia sw ; , A Coovadia, Sunnybrook & Women's College Health Sciences Centre, Toronto, ON, Canada; S F South, Ortho-Clinical Diagnostics, Scottsdale, AZ Background: Pretransfusion testing automation offers great opportunities for resource optimization; however, that optimization will only be realized with keen understanding of process, customer demand, and any instrument's capability. We recently implemented full automation with ORTHO ProVue PV ; , recognizing that suboptimal processes were time, capacity, and revenue lost forever. The need to continually look for ways to optimize resources and enhance customer satisfaction challenged us to look closely at the PV order entry process with a workflow study. Methods: The study format looked at Type and Screen T&S ; testing, using 2 sets of 8 samples. Times were recorded for when the first and last samples in each Set were loaded. Set 2 could not be started until the PV was done pipetting all reagents and samples for Set 1. Various timings were documented, such as when the first and last results of the first and last samples in each set were available. Results: Depending on how T&S testing was ordered with the PV software, timings were different. These timings are shown in the table. Ordering T&S as two separate tests ABO D and Ab or antibody screen ; took 16 seconds longer and resulted in longer times before Set 2 could be loaded and before T&S results were available. Ordering T&S as two tests allowed for faster availability of ABO D results for the 1st sample in both Sets. Conclusion: If ABO D test results are needed sooner than Ab screen results, it is better to order the T&S as 2 separate tests. This will provide ABO D results at 36 min., irrespective of which Set. If ABO D results are not needed as quickly but total test results are needed faster, then it is.

Copegus without prescription